FemmePharma currently has a product to
treat urinary incontinence in Phase 2 and has two other products in the areas
of mastalgia, and dysfunctional uterine bleeding, all in preclinical
development. Patients continued to be followed through
Month 6 and data on the durability of these effects will be presented.medreviews.

This press release contains forward-looking statements regarding
Threshold's TH-070 product candidate, clinical trial plans, anticipated
clinical trial results, and the potential therapeutic benefits of TH-070 for
BPH.

detect urological

The endometriosis market in the United States has been estimated
to be $2. For more information about FemmePharma please visit its website
at http://www.

men tract

Dr.

About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery, development
and commercialization of small molecule therapeutics based on Metabolic
Targeting, an approach that offers broad potential to treat most solid tumors
and certain other diseases.thresholdpharm.

urological nutrition

Concerned with disorders and treatment of the urinary tract in both men and women and the reproductive tract in men.

infection treatment

These statements involve risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking statements .

reproductive relieve

5 billion. The cause of endometriosis is
not known and morbidity associated with this women's disease can be
considerable.

relieve prostate

,
parent of FemmePharma Global Healthcare, Inc. Dr.D. Glandular prostate epithelial cells -- cells that overgrow in BPH
-- are unique in that they are dependent on glycolysis for energy production.com.
Potential risks and uncertainties include, but are not limited to, Threshold's
ability to initiate, enroll and complete its anticipated clinical trials, the
results of such clinical trials (including unanticipated product side-effects
or safety issues as well as efficacy data), the time and expense required to
conduct such clinical trials, Threshold's ability to obtain regulatory
approval for its product candidates based on such clinical trials and
Threshold 's ability to protect and enforce intellectual property rights
regarding TH-070.com) under the heading "Investors".

infections conditions

Michael Brawer, M.

discover bladder

, FemmePharma Holding Company, Inc.
Dr. It can also be progressively severe, with the
risk of urinary tract infection, kidney and bladder damage, bladder stones and
incontinence .

tract prostate

Brawer will present a paper entitled, "28 Day Lonidamine Therapy
Significantly Reduces Prostate Volume and Improves Urine Flow in Symptomatic
Benign Prostatic Hyperplasia: Results of a Phase 2 Open-Label Study" which
will examine the effects of TH-070 on International Prostate Symptom Score
(IPSS), maximum flow rate, residual urine and prostate volume in patients with
BPH.

choice mannose

FemmePharma developed FP1096 using its proprietary PARDEL(R) technology
which allows for the local regional delivery of the active ingredient directly
to the region affected by endometriosis, thus minimizing the systemic exposure
to the active ingredient.
FemmePharma was founded by Gerianne Tringali DiPiano in 1996 to target
high unmet medical needs within the estimated $70 billion women 's healthcare
pharmaceutical market.

diseases bladder

Endometriosis is also the leading cause of infertility among women of
reproductive age, accounting for an estimated 25% to 30% of unexplained
infertility.

com. (Nasdaq: THLD) today announced that Dr. These analyses show that TH-070 improves
symptoms in patients regardless of their baseline disease status in terms of
severity of symptoms and prostate volume.

infection incontinence

The clinical
trial results demonstrate the positive impact of FP1096 on the quality of life
for women with endometriosis.fpghc.S.

urological disorders

to Appear August 2, 2005 in Vancouver

REDWOOD CITY, Calif.gov) and on our website
(http://www.

choice conditions

Data for Threshold Pharmaceuticals' TH -070 to be Presented at American Urological Association Western Section Conference

Food and Drug Administration IND.

concerned relieve

Endometriosis is a painful chronic disease that affects 89 million women
worldwide.

About FemmePharma Global Healthcare, Inc. The information is available online
at the MedReviews website http://www. Phase 2 clinical trial evaluating the dosing, safety and activity of TH-
070 for the treatment of symptomatic benign prostatic hyperplasia (BPH). The company is building a pipeline of drug
candidates that selectively target tumor cells, offering the potential to be
more effective and less toxic to healthy tissues than conventional drugs. For additional information, please visit
http://www.

tract prostate

prostate bladder

, announced that effective May 4,
2005 it entered into an agreement with KV Pharmaceutical Company to divest its
product FP1096 which treats the painful symptoms of endometriosis for an
undisclosed amount that resulted in a significant return to its shareholders. Pain can be debilitating and result in loss of school and work
days. Michael Brawer,
MD, Director of the Northwest Prostate Institute will be presenting at the
upcoming 81st Annual American Urological Association Western Section
Conference to be held July 30 - August 4, 2005 at the Westin Bayshore Resort +
Marina in Vancouver, BC, Canada . Current drug and surgical therapies for BPH are not very
effective, often having slow onset and with side effects ranging from
decreased libido, sexual dysfunction and reduced quality of life to
cardiovascular effects and/or surgical complications.thresholdpharm.

disorders incontinence

In the Phase 2 clinical trials conducted by
FemmePharma, FP1096 demonstrated a reduction of pain associated with
endometriosis and at the same time showed minimal side effects. The findings conclude that the use of the drug induces a rapid and
significant improvement by Day 14 with further improvements at Day 28 that
were sustained through Day 200.

About Benign Prostatic Hyperplasia (BPH)
BPH, also known as benign enlargement of the prostate, is the most common
urological problem among older men and affects an estimated 17 million men in
the United States, 27 million men in five major European countries and 8
million men in Japan.
Threshold's initial clinical focus is the treatment of cancer and benign
prostatic hyperplasia, or BPH, a disease afflicting tens of millions of men
worldwide. Further information regarding these and other risks is
included under the heading "Risk Factors" in Threshold 's Quarterly Report on
10-Q, which was filed with the Securities Exchange Commission on May 13, 2005
and is available from the SEC's website (http://www.sec.

treatment conditions

FemmePharma Global Healthcare Inc. Announces the Divestiture of its Product for the Treatment of Endometriosis to KV Pharmaceutical Company

FemmePharma is committed to developing safe and
effective drugs that minimize or eliminate the systemic side effects
associated with many drug therapies by designing them in a way that is
specifically suited to a woman's physiology with an eye toward the changing
needs of women throughout their lives ., Threshold
Pharmaceuticals Inc.com. We undertake no duty
to update any forward-looking statement made in this news release.

infections presence

The disease occurs when endometrial tissue, or tissue
resembling the lining of the uterus, develops in the pelvic region, which can
cause severe pain during each menstrual cycle. Brawer will discuss analyses of Phase 2
data from Threshold's TH-070 (lonidamine) product candidate for the treatment
of benign prostatic hyperplasia (BPH), which presents a potentially effective
method for providing rapid symptom improvement by targeting overgrown prostate
cells. Additionally , improvements in urine
flow rate correlated well with improvements in symptoms.S. A
Phase 3 multi -center European trial evaluating the safety and efficacy of TH-
070 is expected to commence in mid 2005.

tract consumers

Product Shows Promising Results in Phase 2 Clinical Trials

WAYNE, Pa.
The paper, abstract #09-37, will be presented on Tuesday, August 2 at 2:39
pm during the Andrology plenary session. The company has begun a
U.

About TH-070 and prostate metabolism
TH-070 is thought to disrupt energy metabolism by interfering with
glycolysis.
Preclinical data and Phase 2 data thus far supports that TH-070 presents a
potentially effective method for targeting these prostate cells and may
provide rapid symptom improvement, decreased prostate size, increase in urine
flow, decreased serum PSA, with limited side effects for the treatment of BPH.

concerned reproductive

"We are eager to see this important treatment option enter the market to
help alleviate the pain that endometriosis inflicts on millions of women each
and every day," commented Gerianne Tringali DiPiano , President and CEO of
FemmePharma Global Healthcare, Inc. BPH can restrict the flow of urine, resulting in urine
retention, which can cause weakening of the bladder wall and the inability to
empty the bladder completely.

discover prescription

Dr. Brawer will present additional analyses which support the conclusion
that TH-070 is active in BPH.
Threshold Pharmaceuticals recently initiated a registrational program of
TH-070 under a U.

choice consumers

Detailed results of the study were published by MedReviews in the
quarterly journal of Reviews in Urology.

prescription choice

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)